Vojnikovic B
Ophthalmic Clinic, University Hospital, Rijeka, Yugoslavia.
Ophthalmic Res. 1991;23(1):12-20. doi: 10.1159/000267080.
In a double-blind randomized clinical trial, 79 non-insulin-dependent diabetic subjects with early retinopathy and open-angle glaucoma received orally either three 500-mg capsules of Doxium (calcium dobesilate) daily for 6 months (41 patients) or three placebo capsules daily for the same period (38 patients). At the end of the study statistically significant differences in the Doxium group compared with the placebo group were recorded: intraocular pressure, visual field defects, surface area of retinal hemorrhages, and whole blood and plasma viscosity were reduced (p less than 0.001). Coefficient of outflow facility and serum albumin concentration were increased (p less than 0.001 and p less than 0.02, respectively). These results suggest that increased whole blood viscosity is a risk factor for diabetic retinopathy and for glaucomatous optic nerve damage. They further suggest that Doxium reduces blood hyperviscosity and lowers intraocular pressure, with a beneficial effect on retinal state and visual fields.
在一项双盲随机临床试验中，79名患有早期视网膜病变和开角型青光眼的非胰岛素依赖型糖尿病患者，口服给药6个月，其中41名患者每日服用3粒500毫克的多贝斯（羟苯磺酸钙）胶囊，38名患者每日服用3粒安慰剂胶囊。研究结束时，记录到多贝斯组与安慰剂组相比有统计学显著差异：眼压、视野缺损、视网膜出血面积以及全血和血浆粘度降低（p<0.001）。房水流畅系数和血清白蛋白浓度升高（分别为p<0.001和p<0.02）。这些结果表明，全血粘度升高是糖尿病视网膜病变和青光眼性视神经损伤的危险因素。它们进一步表明，多贝斯可降低血液高粘度并降低眼压，对视网膜状态和视野有有益影响。
